Volume 9 Supplement 2

6th European Workshop on Immune-Mediated Inflammatory Diseases

Open Access

Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis

  • Rosalia Martínez-Pérez1,
  • Julia Uceda1,
  • Mario León1,
  • Sergio Rodríguez1,
  • Alejandro Muñoz1,
  • Francisco Gallo1,
  • Maria Luisa Velloso1 and
  • Jose Luis Marenco1
Journal of Translational Medicine20119(Suppl 2):P46

https://doi.org/10.1186/1479-5876-9-S2-P46

Published: 23 November 2011

Objective

To evaluate the clinical and functional activity of patients with rheumatoid arthritis at one and two years after starting anti-TNF therapy.

Patients and methods

This is a retrospective study of 50 RA patients, who started ANTI-TNF theraphy between June 2006 and july 2009. The main variables in the study were: DAS28, HAQ and pain VAS. We analyzed evolution after 1 year and 2 years from the beginning of the treatment. The comparison with the basal state was made with Student’s t test. The statistical study was analyzed by the SPSS 18,0.

Results

The study includes 50 patients, 66% female, with RF in 76% and erosions in 64%, treated with etanercept (28), adalimumab (13) and infliximab (9). Most of them (70%) had recieved at least 2 FAMES before biological. In the below table we compare changes in clinical parameters for different biologics after one and two years.

Table 1

 

BASAL

12 MONTHS (p basal-12M)

24 MONTHS (p 12M-24M)

EVA (mm)

   

-Etanercept

72,21±16,78

33,20 ± 20,05 (p<0,005)

31,95 ± 27,12 (p=0,39)

-Adalimumab

69,83±20,54

45,00 ± 28,33 (p=0,21)

51,00 ± 28,44 (p=0,16)

-Infliximab

69,78±15,45

42,56 ± 23,41 (p=0,015)

37,71 ± 23,95 (p=0,86)

DAS28

   

-Etanercept

5,88 ± 1,05

2,85 ± 1,16 (p<0,005)

3,09 ± 1,52 (p=0,98)

-Adalimumab

5,73 ± 1,51

4,05 ± 2,43 (p=0,011)

3,90 ± 1,88 (p=0,22)

-Infliximab

6,03 ± 1,87

4,08 ± 1,61 (p=0,021)

3,83 ± 1,66 (p=0,91)

HAQ

   

-Etanercept

1,61 ± 0,61

0,77 ± 0,64 (p <0,005)

0,80 ± 0,73 (p = 0,87)

-Adalimumab

1,63 ± 0,58

1,35 ± 0,63 (p = 0,05)

1,38 ± 0,70 (p =0,58)

-Infliximab

1,45 ± 0,74

1,24 ± 0,72 (p = 0,20)

1,28 ± 0,69 (p = 0,34)

Conclusions

All anti-TNF significantly improve disease activity, functional status and pain VAS after the first year. This improvement continues but not significantly increases the second year.

Etanercept is the only drug with a significant reduction for HAQ, DAS28 and pain VAS.

Authors’ Affiliations

(1)
Rheumatology Unit, Valme University Hospital

Copyright

© Martínez-Pérez et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement